Chimeric PRR T-cell-engager targeting cell surface β-1,3-glucan for invasive candidiasis
PLOS Pathogens · 2025
DOI: 10.1371/journal.ppat.1013508 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von Yu Fang Sun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: beta-Glucans, Candidiasis, Invasive, Lectins, C-Type, T-Lymphocytes. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Invasive candidiasis, primarily caused by Candida albicans , represents the most common fungal disease among hospitalized patients and poses a significant threat to human health. Intrinsic or acquired immunosuppression serves as a critical risk factor predisposing individuals to this disease, while simultaneously reducing the efficacy of conventional antifungal therapies and worsening clinical outcomes. Given the central role of immune dysfunction in the pathogenesis of invasive candidiasis, immunotherapeutic strategies hold substantial promise. We targeted dectin-1, the primary pattern recognition receptor for β-1,3-glucan, by engineering XJ104, a bispecific T-cell engager that fuses dectin-1 to the light chains of an anti-CD3 monoclonal antibody. This construct is designed to bridge Candida β-1,3-glucan with CD3 on T cells, thereby inducing anti- Candida immunity. Our results demonstrate that XJ104 exhibits high specificity for β-1,3-glucan and activates effector cells in a Candida -dependent manner in vitro . In murine models, XJ104 enhances Th1 and Th17 responses and confers significant protection against both C. albicans and non-albicans infections. Crucially, CD3 + T-cell depletion and cytokine neutralization abolished this protection, confirming the T-cell-dependent protective efficacy of XJ104. These results establish that enhancing the endogenous T-cell function represents an effective strategy against invasive candidiasis. In conclusion, our study presents a novel therapeutic approach that bridges T cells and Candida pathogens, promoting robust Candida -specific immunity and controlling invasive infections caused by Candida spp . These findings underscore the potential of XJ104 as a clinically promising immunotherapy for the treatment of invasive candidiasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
- Starmab Biologics (Suzhou) Co., Ltd., Shanghai, China.
- Department of Clinical Laboratory Medicine, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
ORCID-Profile: Mao Mao An
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Sun, Y. F., Guo, S. Y., Wang, S. Q., Li, R. T., Qiu, X. R., Dong, X. C., Liu, S., Shen, H., & An, M. M. (2025). Chimeric PRR T-cell-engager targeting cell surface β-1,3-glucan for invasive candidiasis. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013508
Vancouver
Sun YF, Guo SY, Wang SQ, Li RT, Qiu XR, Dong XC, et al. Chimeric PRR T-cell-engager targeting cell surface β-1,3-glucan for invasive candidiasis. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1013508
BibTeX
@article{Sun2025,
author = {Sun, Yu Fang and Guo, Shi Yu and Wang, Si Qi and Li, Rui Tong and Qiu, Xi Ran and Dong, Xing Chen and Liu, Shuang and Shen, Hui and An, Mao Mao},
title = {Chimeric PRR T-cell-engager targeting cell surface β-1,3-glucan for invasive candidiasis},
journal = {PLOS Pathogens},
year = {2025},
doi = {10.1371/journal.ppat.1013508}
}
EUVIMED